Today we announced new MONSTAR-SCREEN-3 data demonstrating the potential of Myriad's WGS-based Precise MRD™ platform for ultrasensitive #MRD detection after surgery in resectable colorectal and pancreatic cancers.
👉See more: https://bit.ly/4snogy2
#ctDNA #ESMO26 #coloncancer
110 views · 0 likes · 1 repost · 0 replies
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.orgPlasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
https://esmocongress.esmo.orgCharacterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgClinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors
https://esmocongress.esmo.orgctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgUltrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study
https://esmocongress.esmo.orgSource: Myriad Genetics · x.com